The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Editorial
PreviousPrevious
Volume 332:330-331 February 2, 1995 Number 5
NextNext

Methotrexate for Chronic Diseases in Adults

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
-Purchase this article

Commentary
-Letters

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-PubMed Citation
More than 40 years after the initial report1 of a beneficial effect of aminopterin, the parent compound of methotrexate, in rheumatoid arthritis and psoriasis, there is a resurgence of interest in the use of methotrexate in autoimmune and inflammatory diseases. In this issue of the Journal, Feagan and colleagues report that in a 16-week double-blind trial, intramuscular methotrexate (25 mg once weekly) was more effective than placebo in improving symptoms and reducing requirements for prednisone in patients with chronically active Crohn's disease.2 A greater proportion of patients were in clinical remission in the methotrexate group (39.4 percent) than in the . . . [Full Text of this Article]

References


Related Letters:

Methotrexate for Chronic Diseases in Adults
Fogari R. A., Hoch S., Zonneveld I.M., Bos J.D., Weinblatt M. E.
Extract | Full Text  
N Engl J Med 1995; 332:1791-1792, Jun 29, 1995. Correspondence

This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.